Rapport Therapeutics, Inc. (NASDAQ:RAPP – Get Free Report) COO Cheryl Gault sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 30th. The stock was sold at an average price of $33.19, for a total value of $331,900.00. Following the sale, the chief operating officer directly owned 139,914 shares in the company, valued at approximately $4,643,745.66. The trade was a 6.67% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Rapport Therapeutics Stock Performance
Shares of RAPP stock opened at $32.17 on Friday. Rapport Therapeutics, Inc. has a 1 year low of $23.75 and a 1 year high of $52.93. The stock has a market cap of $1.54 billion, a PE ratio of -10.58 and a beta of 1.22. The business’s fifty day moving average is $43.60 and its 200-day moving average is $38.94.
Rapport Therapeutics (NASDAQ:RAPP – Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($1.19) earnings per share for the quarter, missing the consensus estimate of ($1.12) by ($0.07). Equities research analysts predict that Rapport Therapeutics, Inc. will post -4.09 earnings per share for the current year.
Wall Street Analysts Forecast Growth
View Our Latest Analysis on RAPP
Institutional Investors Weigh In On Rapport Therapeutics
Several hedge funds have recently made changes to their positions in the company. Algert Global LLC purchased a new position in Rapport Therapeutics during the 2nd quarter worth approximately $9,327,000. Johnson & Johnson acquired a new stake in shares of Rapport Therapeutics in the second quarter worth $74,360,823. Legal & General Group Plc purchased a new position in shares of Rapport Therapeutics during the second quarter valued at $940,000. Walleye Capital LLC acquired a new position in Rapport Therapeutics during the second quarter valued at $4,257,000. Finally, Bank of New York Mellon Corp purchased a new stake in Rapport Therapeutics in the 2nd quarter worth about $3,426,000.
About Rapport Therapeutics
Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for neurological and psychiatric disorders. The company uses its proprietary RAP platform to identify and target synaptic receptor-associated proteins, which can influence the activity, distribution and function of receptors involved in the central nervous system.
Rapport’s lead clinical program is relutrigine, also known as RAP-219, an orally administered small-molecule therapy being developed for focal epilepsy.
Featured Articles
- Five stocks we like better than Rapport Therapeutics
- Carnival and CarMax Pop on Strong Earnings, but Challenges Remain
- 3 Income Stocks Under $30 That Yield More Than the 10-Year Treasury Note
- 3 AI Winners, 3 Very Different Paths to Higher Margins
- Plexus Is Booming—But Can the Growth Story Last?
Receive News & Ratings for Rapport Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rapport Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
